Literature DB >> 25463545

Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.

Thierry Thévenot1, Christophe Bureau2, Frédéric Oberti3, Rodolphe Anty4, Alexandre Louvet5, Aurélie Plessier6, Marika Rudler7, Alexandra Heurgué-Berlot8, Isabelle Rosa9, Nathalie Talbodec10, Thong Dao11, Violaine Ozenne12, Nicolas Carbonell13, Xavier Causse14, Odile Goria15, Anne Minello16, Victor De Ledinghen17, Roland Amathieu18, Hélène Barraud19, Eric Nguyen-Khac20, Claire Becker21, Thierry Paupard22, Danielle Botta-Fridlung23, Naceur Abdelli24, François Guillemot25, Elisabeth Monnet26, Vincent Di Martino26.   

Abstract

BACKGROUND & AIMS: Albumin infusion improves renal function and survival in cirrhotic patients with spontaneous bacterial peritonitis (SBP) but its efficacy in other types of infections remains unknown. We investigated this issue through a multicenter randomized controlled trial.
METHODS: A total of 193 cirrhotic patients with a Child-Pugh score greater than 8 and sepsis unrelated to SBP were randomly assigned to receive antibiotics plus albumin (1.5 g/kg on day 1 and 1g/kg on day 3; albumin group [ALB]: n=96) or antibiotics alone (control group [CG]: n=97). The primary endpoint was the 3-month renal failure rate (increase in creatinine ⩾50% to reach a final value ⩾133 μmol/L). The secondary endpoint was 3-month survival rate.
RESULTS: Forty-seven (24.6%) patients died (ALB: n=27 vs. CG: n=20; 3-month survival: 70.2% vs. 78.3%; p=0.16). Albumin infusion delayed the occurrence of renal failure (mean time to onset, ALB: 29.0 ± 21.8 vs. 11.7 ± 9.1 days, p=0.018) but the 3-month renal failure rate was similar (ALB: 14.3% vs. CG: 13.5%; p=0.88). By multivariate analysis, MELD score (p<0.0001), pneumonia (p=0.0041), hyponatremia (p=0.031) and occurrence of renal failure (p<0.0001) were predictors of death. Of note, pulmonary edema developed in 8/96 (8.3%) patients in the albumin group of whom two died, one on the day and the other on day 33 following albumin infusion.
CONCLUSIONS: In cirrhotic patients with infections other than SBP, albumin infusion delayed onset of renal failure but did not improve renal function or survival at 3 months. Infusion of large amounts of albumin should be cautiously administered in the sickest cirrhotic patients.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liver cirrhosis; Portal hypertension; Prognosis; Renal failure; Sepsis

Mesh:

Substances:

Year:  2014        PMID: 25463545     DOI: 10.1016/j.jhep.2014.11.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

Review 1.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

2.  Spontaneous bacteremia and spontaneous bacterial peritonitis in cirrhosis: two infections but similar outcomes?

Authors:  Rakhi Maiwall
Journal:  Hepatol Int       Date:  2018-03-27       Impact factor: 6.047

Review 3.  Sepsis-induced acute kidney injury in patients with cirrhosis.

Authors:  Paolo Angeli; Marta Tonon; Chiara Pilutti; Filippo Morando; Salvatore Piano
Journal:  Hepatol Int       Date:  2015-07-04       Impact factor: 6.047

4.  Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference.

Authors:  Manuel Tufoni; Giacomo Zaccherini; Paolo Caraceni
Journal:  Ann Transl Med       Date:  2019-09

Review 5.  Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference.

Authors:  Rinaldo Bellomo; Claudio Ronco; Ravindra L Mehta; Pierre Asfar; Julie Boisramé-Helms; Michael Darmon; Jean-Luc Diehl; Jacques Duranteau; Eric A J Hoste; Joannes-Boyau Olivier; Matthieu Legrand; Nicolas Lerolle; Manu L N G Malbrain; Johan Mårtensson; Heleen M Oudemans-van Straaten; Jean-Jacques Parienti; Didier Payen; Sophie Perinel; Esther Peters; Peter Pickkers; Eric Rondeau; Miet Schetz; Christophe Vinsonneau; Julia Wendon; Ling Zhang; Pierre-François Laterre
Journal:  Ann Intensive Care       Date:  2017-05-04       Impact factor: 6.925

Review 6.  Albumin in chronic liver disease: structure, functions and therapeutic implications.

Authors:  Rosaria Spinella; Rohit Sawhney; Rajiv Jalan
Journal:  Hepatol Int       Date:  2015-09-29       Impact factor: 6.047

7.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

Review 8.  Bacterial infections in cirrhosis: A critical review and practical guidance.

Authors:  Chalermrat Bunchorntavakul; Naichaya Chamroonkul; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2016-02-28

Review 9.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 10.  Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

Authors:  Jonel Trebicka; Thomas Reiberger; Wim Laleman
Journal:  Visc Med       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.